Skip to content
Original
mp.weixin.qq.com·· 2 days agoScore74

ESMO 2026: Chia Tai Tianqing Presents 15 Clinical Studies of Anlotinib, Benmelstobart and Penpulimab

In brief

At ESMO 2026, Chia Tai Tianqing presented 15 clinical studies of anlotinib, benmelstobart and penpulimab, spanning lung cancer, soft tissue sarcoma, esophageal cancer, pancreatic cancer and breast cancer.

Source: mp.weixin.qq.com · mp.weixin.qq.com

#Conference#Oncology#Immunotherapy#Small molecules & degraders#Biomarkers
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.